Search Results - "CASTRATION"

Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.

Authors: Iwamoto H Hori T Inaba T et al.

Source: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2025 Nov; Vol. 32 (11), pp. 1640-1649. Date of Electronic Publication: 2025 Aug 19.

Publication Type: Journal Article

Journal Info: Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Androgen Antagonists*/therapeutic use , Androgen Receptor Antagonists*/therapeutic use , Adenocarcinoma*/mortality , Adenocarcinoma*/drug therapy , Adenocarcinoma*/secondary , Adenocarcinoma*/pathology, Humans ; Male ; Retrospective Studies ; Aged ; Prognosis ; Middle Aged ; Disease Progression ; Aged, 80 and over ; Time Factors ; Kaplan-Meier Estimate ; Follow-Up Studies ; Neoplasm Grading

Prognostic value of whole-body diffusion-weighted imaging with background body signal suppression in CRPC patients undergoing Ra-223 therapy: an exploratory analysis.

Authors: Kono Y Utsunomiya K Nakamura S et al.

Source: Japanese journal of radiology [Jpn J Radiol] 2025 Oct; Vol. 43 (10), pp. 1688-1695. Date of Electronic Publication: 2025 Jun 17.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: Japan NLM ID: 101490689 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1867-108X (Electronic) Linking ISSN: 18671071 NLM ISO Abbreviation: Jpn J Radiol Subsets: MEDLINE

MeSH Terms: Diffusion Magnetic Resonance Imaging*/methods , Whole Body Imaging*/methods , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Prostatic Neoplasms, Castration-Resistant*/pathology , Bone Neoplasms*/secondary , Bone Neoplasms*/radiotherapy , Bone Neoplasms*/diagnostic imaging, Humans ; Male ; Aged ; Retrospective Studies ; Prognosis ; Middle Aged ; Aged, 80 and over ; Treatment Outcome

Initial Multicenter Experience with [ ¹⁶¹ Tb]Tb-PSMA in [ ¹⁷⁷ Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.

Authors: Kucuk NO Coskun N Araz M et al.

Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2025 Dec 03; Vol. 66 (12), pp. 1921-1926. Date of Electronic Publication: 2025 Dec 03.

Publication Type: Journal Article; Multicenter Study; Clinical Trial

Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Lutetium*/therapeutic use, Humans ; Male ; Aged ; Middle Aged ; Neoplasm Metastasis ; Radioisotopes/therapeutic use ; Treatment Outcome ; Positron Emission Tomography Computed Tomography ; Radiopharmaceuticals/therapeutic use ; Prospective Studies ; Glutamate Carboxypeptidase II ; Aged, 80 and over ; Heterocyclic Compounds, 1-Ring ; Prostate-Specific Antigen

Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based Study.

Authors: Kobayashi K Tokunaga T Nagao K et al.

Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102437. Date of Electronic Publication: 2025 Sep 16.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Androgen Receptor Antagonists*/therapeutic use, Humans ; Male ; Retrospective Studies ; Aged ; Benzamides/therapeutic use ; Nitriles/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Phenylthiohydantoin/administration & dosage ; Thiohydantoins/therapeutic use ; Thiohydantoins/administration & dosage ; Middle Aged ; Androstenes ; Aged, 80 and over ; Prostate-Specific Antigen/blood ; Treatment Outcome ; Receptors, Androgen/metabolism

UK real-world data of radium-223 dichloride in metastatic prostate cancer.

Authors: Randhawa M Buchanan G Stratton IM et al.

Corporate Authors: Randhawa M Buchanan G Stratton IM et al.

Source: Nuclear medicine communications [Nucl Med Commun] 2025 Dec 01; Vol. 46 (12), pp. 1155-1162. Date of Electronic Publication: 2025 Oct 15.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8201017 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5628 (Electronic) Linking ISSN: 01433636 NLM ISO Abbreviation: Nucl Med Commun Subsets: MEDLINE

MeSH Terms: Radium*/therapeutic use , Radium*/adverse effects , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/radiotherapy, Humans ; Male ; Aged ; United Kingdom ; Middle Aged ; Quality of Life ; Neoplasm Metastasis ; Aged, 80 and over ; Radioisotopes/therapeutic use ; Radioisotopes/adverse effects ; Treatment Outcome

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors.

Authors: Wu Z Zhang J Li L et al.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2426755. Date of Electronic Publication: 2025 Feb 03.

Publication Type: Journal Article; Review

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Biomarkers, Tumor*/metabolism , Biomarkers, Tumor*/genetics, Humans ; Male ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; CTLA-4 Antigen/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Microsatellite Instability ; Neoplasm Metastasis

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.

Authors: Oishi T Fujita N Kawashima Y et al.

Source: International journal of clinical oncology [Int J Clin Oncol] 2025 Dec; Vol. 30 (12), pp. 2635-2642. Date of Electronic Publication: 2025 Sep 14.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/blood , Drug Resistance, Neoplasm* , Androgen Receptor Antagonists*/therapeutic use , Androgen Receptor Antagonists*/pharmacology , Androgen Receptor Antagonists*/administration & dosage, Humans ; Male ; Aged ; Retrospective Studies ; Prostate-Specific Antigen/blood ; Middle Aged ; Receptors, Androgen/metabolism ; Aged, 80 and over ; Signal Transduction/drug effects

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.

Authors: Perimbeti S Jamroze A Gopalakrishnan D et al.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Nov 29; Vol. 95 (1), pp. 115. Date of Electronic Publication: 2025 Nov 29.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Sulfonamides/adverse effects ; Aged ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Benzamides/administration & dosage ; Nitriles/administration & dosage ; Phenylthiohydantoin/administration & dosage ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/pharmacokinetics ; Middle Aged ; Maximum Tolerated Dose ; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors ; Aged, 80 and over ; Dose-Response Relationship, Drug

Elderly Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Therapy and Does Comorbidity Matter.

Authors: Ozberk U Esen SA Uguz A et al.

Source: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2025 Nov 20; Vol. 61 (11). Date of Electronic Publication: 2025 Nov 20.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms*, Humans ; Male ; Aged, 80 and over ; Retrospective Studies ; Aged ; Benzamides/therapeutic use ; Nitriles/therapeutic use ; Comorbidity ; Phenylthiohydantoin/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; Androgen Antagonists/therapeutic use ; Anilides/therapeutic use ; Tosyl Compounds/therapeutic use

Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression.

Authors: Wen H Maheremu M Zhang K et al.

Source: Molecular biomedicine [Mol Biomed] 2025 Nov 17; Vol. 6 (1), pp. 112. Date of Electronic Publication: 2025 Nov 17.

Publication Type: Journal Article

Journal Info: Publisher: Springer Singapore Country of Publication: Singapore NLM ID: 9918283581406676 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-8651 (Electronic) Linking ISSN: 26628651 NLM ISO Abbreviation: Mol Biomed Subsets: MEDLINE

MeSH Terms: Receptors, Androgen*/metabolism , Receptors, Androgen*/genetics , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/genetics , Repressor Proteins*/metabolism , Repressor Proteins*/genetics , DNA Helicases*/metabolism , DNA Helicases*/genetics , RNA Recognition Motif Proteins*/metabolism , RNA Recognition Motif Proteins*/genetics , Poly-ADP-Ribose Binding Proteins*/metabolism , Poly-ADP-Ribose Binding Proteins*/genetics , DNA-Binding Proteins*/metabolism , DNA-Binding Proteins*/genetics , Neoplasm Proteins*/metabolism , Neoplasm Proteins*/genetics , Nuclear Proteins*/metabolism , Histone-Lysine N-Methyltransferase*/metabolism, Male ; Humans ; Cell Line, Tumor ; Disease Progression ; Signal Transduction/drug effects ; Nitriles ; Benzamides ; Gene Expression Regulation, Neoplastic ; Animals ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/pharmacology ; RNA Helicases

KDM3B suppresses castration-resistance prostate cancer cell proliferation by promoting PTEN expression.

Authors: Zhang P Liu Y Pan L et al.

Source: European journal of medical research [Eur J Med Res] 2025 Nov 07; Vol. 30 (1), pp. 1090. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 9517857 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-783X (Electronic) Linking ISSN: 09492321 NLM ISO Abbreviation: Eur J Med Res Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/metabolism , Jumonji Domain-Containing Histone Demethylases*/metabolism , Jumonji Domain-Containing Histone Demethylases*/genetics , PTEN Phosphohydrolase*/metabolism , PTEN Phosphohydrolase*/genetics , Gene Expression Regulation, Neoplastic* , Minor Histocompatibility Antigens*/metabolism , Minor Histocompatibility Antigens*/genetics, Male ; Humans ; Cell Proliferation ; Animals ; Cell Line, Tumor ; Mice

Rewriting androgen-targeted therapy resistance with non-coding RNAs in prostate cancer treatment.

Authors: Liyanage C Clements J Batra J

Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2025 Nov 05; Vol. 33 (11), pp. 5355-5372. Date of Electronic Publication: 2025 Jul 28.

Publication Type: Journal Article; Review

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

MeSH Terms: Drug Resistance, Neoplasm*/genetics , RNA, Untranslated*/genetics , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/metabolism , Prostatic Neoplasms*/therapy , Androgens*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/drug therapy, Humans ; Male ; Gene Expression Regulation, Neoplastic/drug effects ; Animals ; Biomarkers, Tumor/genetics ; Signal Transduction ; Molecular Targeted Therapy

Verbascoside Suppresses Epithelial-Mesenchymal Transition and Mitochondrial Biogenesis by Targeting Anti-senescence Signaling in Castration-resistant Prostate Cancer.

Authors: Mai HC Hsieh PF Wu CH et al.

Source: Cancer genomics & proteomics [Cancer Genomics Proteomics] 2025 Nov-Dec; Vol. 22 (6), pp. 1044-1060.

Publication Type: Journal Article

Journal Info: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 101188791 Publication Model: Print Cited Medium: Internet ISSN: 1790-6245 (Electronic) Linking ISSN: 11096535 NLM ISO Abbreviation: Cancer Genomics Proteomics Subsets: MEDLINE

MeSH Terms: Epithelial-Mesenchymal Transition*/drug effects , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Glucosides*/pharmacology , Phenols*/pharmacology , Cellular Senescence*/drug effects , Organelle Biogenesis* , Mitochondria*/drug effects , Mitochondria*/metabolism, Male ; Humans ; Signal Transduction/drug effects ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Oxidative Stress/drug effects ; Polyphenols

Targeting neutral sphingomyelinase 2 by cambinol decreases cell proliferation and migration of metastatic castration-resistant prostate cancer cells.

Authors: Dawud D Kartamyshev M Kumar T et al.

Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2025 Nov; Vol. 392 (11), pp. 103739. Date of Electronic Publication: 2025 Oct 09.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

MeSH Terms: Cell Movement*/drug effects , Cell Proliferation*/drug effects , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/enzymology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Sphingomyelin Phosphodiesterase*/antagonists & inhibitors , Sphingomyelin Phosphodiesterase*/metabolism, Male ; Humans ; Cell Line, Tumor ; Neoplasm Metastasis ; Cell Survival/drug effects ; Thiohydantoins/pharmacology ; Signal Transduction/drug effects

Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study.

Authors: Papet J Augusto-Pelegrin L Christy F et al.

Source: Anti-cancer drugs [Anticancer Drugs] 2025 Nov 01; Vol. 36 (10), pp. 805-811. Date of Electronic Publication: 2025 Oct 08.

Publication Type: Journal Article; Observational Study; Multicenter Study

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/pathology , Androgen Receptor Antagonists*/therapeutic use , Androgen Receptor Antagonists*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Prospective Studies ; Aged ; France/epidemiology ; Middle Aged ; Aged, 80 and over ; Survival Rate ; Neoplasm Metastasis ; Progression-Free Survival

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.

Authors: Yamamoto Y Fujimoto S Hashimoto M et al.

Source: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2025 Nov; Vol. 32 (11), pp. 1650-1659. Date of Electronic Publication: 2025 Aug 14.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-2042 (Electronic) Linking ISSN: 09198172 NLM ISO Abbreviation: Int J Urol Subsets: MEDLINE

MeSH Terms: Androgen Antagonists*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/pathology , Androgen Receptor Antagonists*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Aged ; Aged, 80 and over ; Retrospective Studies ; Nitriles/therapeutic use ; Nitriles/administration & dosage ; Tosyl Compounds/therapeutic use ; Tosyl Compounds/administration & dosage ; Anilides/therapeutic use ; Anilides/administration & dosage ; Treatment Outcome ; Propensity Score

Pharmacokinetics and dosimetry of [ ¹⁷⁷ Lu]Lu-PSMA-617 and [ ⁶⁸ Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC.

Authors: Takano S Inaki A Hirata K et al.

Source: Annals of nuclear medicine [Ann Nucl Med] 2025 Nov; Vol. 39 (11), pp. 1201-1212. Date of Electronic Publication: 2025 Jul 10.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Springer Japan Country of Publication: Japan NLM ID: 8913398 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1864-6433 (Electronic) Linking ISSN: 09147187 NLM ISO Abbreviation: Ann Nucl Med Subsets: MEDLINE

MeSH Terms: Heterocyclic Compounds, 1-Ring*/pharmacokinetics , Heterocyclic Compounds, 1-Ring*/adverse effects , Heterocyclic Compounds, 1-Ring*/therapeutic use , Dipeptides*/pharmacokinetics , Dipeptides*/adverse effects , Dipeptides*/therapeutic use , Lutetium* , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Glutamate Carboxypeptidase II*/metabolism, Humans ; Male ; Gallium Radioisotopes ; Aged ; Middle Aged ; Radiometry ; Radioisotopes ; Aged, 80 and over ; Japan ; Prospective Studies ; East Asian People ; Antigens, Surface ; Gallium Isotopes ; Prostate-Specific Antigen

Lipid Metabolic Reprogramming During Progression to Castration-resistant Prostate Cancer Identified by Quantitative Proteomics.

Authors: Sim H Bae S Park CW et al.

Source: Cancer genomics & proteomics [Cancer Genomics Proteomics] 2025 Nov-Dec; Vol. 22 (6), pp. 940-952.

Publication Type: Journal Article

Journal Info: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 101188791 Publication Model: Print Cited Medium: Internet ISSN: 1790-6245 (Electronic) Linking ISSN: 11096535 NLM ISO Abbreviation: Cancer Genomics Proteomics Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/pathology , Proteomics*/methods , Lipid Metabolism*, Male ; Humans ; Disease Progression ; Cell Line, Tumor ; Fatty Acids/metabolism ; Metabolic Reprogramming

Serum Markers as predictors for treatment benefit in castration-resistant prostate cancer.

Authors: Szarvas T Kramer G Jagarlamudi K et al.

Source: Urologic oncology [Urol Oncol] 2025 Nov; Vol. 43 (11), pp. 664.e11-664.e17. Date of Electronic Publication: 2025 Aug 06.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

MeSH Terms: Prostatic Neoplasms, Castration-Resistant*/blood , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/mortality , Biomarkers, Tumor*/blood , Androgen Receptor Antagonists*/therapeutic use, Humans ; Male ; Aged ; Docetaxel/therapeutic use ; Middle Aged ; Thymidine Kinase/blood ; Prostate-Specific Antigen/blood ; Treatment Outcome ; Aged, 80 and over

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape.

Authors: Chen Y Cao J Huang R et al.

Source: Cancer medicine [Cancer Med] 2025 Nov; Vol. 14 (21), pp. e71298.

Publication Type: Journal Article; Review

Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

MeSH Terms: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms*/drug therapy, Humans ; Male ; Clinical Trials as Topic/statistics & numerical data